What is Immunocore Holdings Plc's earnings per share (EPS)?

Immunocore Holdings Plc (IMCR) reported diluted earnings per share of $-0.71 for fiscal year 2025. This represents a 30.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Immunocore Holdings Plc Financials

IMCR

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Immunocore Holdings Plc (IMCR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI IMCR FY2025 2026-05-06

Immunocore’s near-pure gross margin model is steadily narrowing losses, but cash self-sufficiency still has not arrived.

By FY2025, revenue had more than doubled versus FY2022 to $400.0M while net margin narrowed to -8.9%; that pairing shows scale is absorbing more of the fixed cost base. But operating cash flow slipped from $26.1M in FY2024 to -$10.7M in FY2025 despite the smaller loss, suggesting the prior year’s cash positivity was helped by working-capital timing rather than a fully self-funding model.

With gross margin still near 98.7%, production cost is not the bottleneck. The real swing factor is expense absorption: FY2025 R&D and SG&A reached $274.9M and $165.4M, so added revenue matters mainly because it spreads a large scientific and commercial cost base.

The balance sheet is liquid but leveraged in a specific way: cash ended FY2025 at $467.7M and the current ratio was 4.0x, so near-term obligations do not look like the immediate constraint. But total liabilities of $686.2M versus equity of $381.0M mean staying power depends on preserving that cash cushion while losses continue.

Financial Health Signals

Financial Health Score 66/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Immunocore Holdings Plc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

100

Dilution

R&D Intensity

Revenue Progress

Balance Sheet

Altman Z-Score Distress

1.46

Immunocore Holdings Plc scores 1.46, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.7B) relative to total liabilities ($686.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/8

Immunocore Holdings Plc passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.30x

For every $1 of reported earnings, Immunocore Holdings Plc generates $0.30 in operating cash flow (-$10.7M OCF vs -$35.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-3.7x

Immunocore Holdings Plc earns $-3.7 in operating income for every $1 of interest expense (-$45.4M vs $12.2M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$400.0M

YoY+29.0%

Immunocore Holdings Plc generated $400.0M in revenue in fiscal year 2025. This represents an increase of 29.0% from the prior year.

EBITDA

-$42.3M

YoY+36.2%

Immunocore Holdings Plc's EBITDA was -$42.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 36.2% from the prior year.

Net Income

-$35.5M

YoY+30.5%

Immunocore Holdings Plc reported -$35.5M in net income in fiscal year 2025. This represents an increase of 30.5% from the prior year.

EPS (Diluted)

$-0.71

YoY+30.4%

Immunocore Holdings Plc earned $-0.71 per diluted share (EPS) in fiscal year 2025. This represents an increase of 30.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$15.1M

YoY-172.1%

Immunocore Holdings Plc generated -$15.1M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 172.1% from the prior year.

Cash & Debt

$467.7M

YoY+2.6%

Immunocore Holdings Plc held $467.7M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

$0.00

Immunocore Holdings Plc paid $0.00 per share in dividends in fiscal year 2025.

Shares Outstanding

51M

YoY+1.3%

Immunocore Holdings Plc had 51M shares outstanding in fiscal year 2025. This represents an increase of 1.3% from the prior year.

Margins & Returns

Gross Margin

98.7%

YoY-0.4pp

Immunocore Holdings Plc's gross margin was 98.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.4 percentage points from the prior year.

Operating Margin

-11.3%

YoY+11.4pp

Immunocore Holdings Plc's operating margin was -11.3% in fiscal year 2025, reflecting core business profitability. This is up 11.4 percentage points from the prior year.

Net Margin

-8.9%

YoY+7.6pp

Immunocore Holdings Plc's net profit margin was -8.9% in fiscal year 2025, showing the share of revenue converted to profit. This is up 7.6 percentage points from the prior year.

Return on Equity

-9.3%

YoY+4.8pp

Immunocore Holdings Plc's ROE was -9.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 4.8 percentage points from the prior year.

Capital Allocation

R&D Spending

$274.9M

YoY+23.7%

Immunocore Holdings Plc invested $274.9M in research and development in fiscal year 2025. This represents an increase of 23.7% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$4.3M

YoY-16.1%

Immunocore Holdings Plc invested $4.3M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 16.1% from the prior year.

IMCR Income Statement

Metric	FY25	FY24	FY23	FY22	FY21
Revenue	$400.0M+29.0%	$310.2M+24.4%	$249.4M+43.1%	$174.4M+377.9%	$36.5M
Cost of Revenue	$5.1M+86.3%	$2.7M+163.4%	$1.0M-4.8%	$1.1M	$0
Gross Profit	$394.9M+28.4%	$307.5M+23.8%	$248.4M+43.4%	$173.3M+374.9%	$36.5M
R&D Expenses	$274.9M+23.7%	$222.2M+35.8%	$163.5M+60.5%	$101.9M+1.7%	$100.2M
SG&A Expenses	$165.4M+6.2%	$155.8M+7.8%	$144.5M+17.4%	$123.1M+11.0%	$110.8M
Operating Income	-$45.4M+35.6%	-$70.5M-18.1%	-$59.6M-15.4%	-$51.7M+70.4%	-$174.6M
Interest Expense	$12.2M-35.4%	$18.8M+265.6%	$5.2M-4.7%	$5.4M-2.9%	$5.6M
Income Tax	$16.4M+987.2%	-$1.9M+67.0%	-$5.6M-148.1%	$11.7M+7673.3%	$150K
Net Income	-$35.5M+30.5%	-$51.1M+7.6%	-$55.3M-5.2%	-$52.5M+70.8%	-$180.0M
EPS (Diluted)	$-0.71+30.4%	$-1.02+9.7%	$-1.13+1.7%	$-1.15+72.9%	$-4.24

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$106.7M+2.1%	$104.5M+0.8%	$103.7M+5.8%	$98.0M+4.3%	$93.9M+11.7%	$84.1M+4.7%	$80.2M+6.4%	$75.4M
Cost of Revenue	$434K-83.9%	$2.7M+426.9%	$513K-50.7%	$1.0M+25.2%	$831K+151.8%	$330K-26.3%	$448K-73.8%	$1.7M
Gross Profit	$106.2M+4.4%	$101.8M-1.4%	$103.2M+6.5%	$96.9M+4.2%	$93.0M+11.1%	$83.7M+4.9%	$79.8M+8.3%	$73.7M
R&D Expenses	$61.1M-22.5%	$78.8M+11.7%	$70.6M+2.3%	$69.0M+22.2%	$56.5M-7.2%	$60.9M+15.3%	$52.8M+3.3%	$51.1M
SG&A Expenses	$37.9M-11.2%	$42.6M+7.2%	$39.8M-7.0%	$42.8M+6.5%	$40.2M-5.0%	$42.3M+19.1%	$35.5M-8.0%	$38.6M
Operating Income	$7.3M+137.0%	-$19.7M-174.6%	-$7.2M+51.8%	-$14.9M-311.4%	-$3.6M+81.4%	-$19.5M-128.8%	-$8.5M+46.9%	-$16.0M
Interest Expense	$3.1M-0.1%	$3.1M+0.3%	$3.0M-0.1%	$3.0M+0.7%	$3.0M-57.0%	$7.0M+64.1%	$4.3M+0.3%	$4.3M
Income Tax	$301K-97.9%	$14.3M+2865.9%	$481K-20.6%	$606K-42.9%	$1.1M+201.0%	-$1.1M+60.3%	-$2.6M-277.9%	$1.5M
Net Income	$13.0M+143.2%	-$30.1M-16883.1%	-$177K+98.3%	-$10.3M-305.1%	$5.0M+121.1%	-$23.8M-372.1%	$8.7M+175.2%	-$11.6M
EPS (Diluted)	$0.25	N/A	$0.00+100.0%	$-0.20-300.0%	$0.10	N/A	$0.17+173.9%	$-0.23

IMCR Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21
Total Assets	$1.1B+5.7%	$1.0B+69.1%	$597.0M+13.3%	$526.8M	N/A
Current Assets	$996.7M+7.2%	$929.9M+75.8%	$528.8M+11.6%	$474.0M	N/A
Cash & Equivalents	$467.7M+2.6%	$455.7M+3.0%	$442.6M+10.0%	$402.5M+25.3%	$321.1M
Inventory	$6.7M+23.8%	$5.4M+21.0%	$4.5M+550.4%	$692K	N/A
Accounts Receivable	N/A	$63.0M+21.0%	$52.1M+55.1%	$33.6M	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$686.2M+5.8%	$648.8M+184.4%	$228.2M+21.5%	$187.9M	N/A
Current Liabilities	$246.7M+16.3%	$212.2M+52.6%	$139.0M+37.9%	$100.8M	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A
Total Equity	$381.0M+5.6%	$360.7M-2.2%	$368.8M+8.8%	$338.9M+45.0%	$233.7M
Retained Earnings	-$831.3M-4.5%	-$795.8M-6.9%	-$744.7M-8.0%	-$689.4M	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$1.1B+0.5%	$1.1B-3.2%	$1.1B+1.9%	$1.1B+5.3%	$1.0B+1.8%	$1.0B-6.9%	$1.1B+6.0%	$1.0B
Current Assets	$1.0B+0.7%	$996.7M-2.6%	$1.0B+2.1%	$1.0B+5.7%	$948.6M+2.0%	$929.9M-7.6%	$1.0B+5.1%	$956.9M
Cash & Equivalents	$452.7M-3.2%	$467.7M-6.2%	$498.4M+2.1%	$487.9M+2.3%	$476.8M+4.6%	$455.7M-15.3%	$537.8M+6.5%	$505.0M
Inventory	$8.3M+22.4%	$6.7M+19.2%	$5.7M+3.6%	$5.5M-19.8%	$6.8M+24.9%	$5.4M+20.5%	$4.5M+30.5%	$3.5M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	$63.0M-1.0%	$63.7M+5.7%	$60.2M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$678.4M-1.1%	$686.2M-2.8%	$705.9M+1.7%	$693.9M+6.8%	$649.5M+0.1%	$648.8M-8.2%	$706.8M+6.4%	$664.2M
Current Liabilities	$240.1M-2.7%	$246.7M+44.8%	$170.4M+0.2%	$170.1M+14.0%	$149.2M-29.7%	$212.2M-20.3%	$266.2M+43.8%	$185.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	$438.7M-3.1%	$452.5M
Total Equity	$393.7M+3.3%	$381.0M-3.9%	$396.6M+2.1%	$388.5M+2.6%	$378.5M+4.9%	$360.7M-4.5%	$377.8M+5.2%	$359.1M
Retained Earnings	-$818.3M+1.6%	-$831.3M-3.8%	-$801.2M0.0%	-$801.0M-1.3%	-$790.7M+0.6%	-$795.8M-3.1%	-$772.0M+1.1%	-$780.7M

IMCR Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21
Operating Cash Flow	-$10.7M-141.1%	$26.1M+786.4%	$2.9M+106.0%	-$49.2M+65.6%	-$143.1M
Capital Expenditures	$4.3M-16.1%	$5.2M-4.6%	$5.4M+146.3%	$2.2M+58.9%	$1.4M
Free Cash Flow	-$15.1M-172.1%	$20.9M+940.6%	-$2.5M+95.2%	-$51.4M+64.4%	-$144.5M
Investing Cash Flow	-$16.3M+95.4%	-$355.1M-6446.2%	-$5.4M-146.9%	-$2.2M-71.6%	-$1.3M
Financing Cash Flow	$12.4M-96.4%	$343.9M+901.2%	$34.3M-76.4%	$145.4M-49.5%	$288.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$13.8M+57.8%	-$32.7M-632.8%	-$4.5M-117.2%	$26.0M+5868.7%	$435K+103.1%	-$14.0M-166.0%	$21.1M-10.0%	$23.5M
Capital Expenditures	$1.8M-38.2%	$2.9M+285.0%	$748K+80.7%	$414K+38.9%	$298K-91.7%	$3.6M+332.9%	$828K+150.2%	$331K
Free Cash Flow	-$15.6M+56.2%	-$35.5M-582.8%	-$5.2M-120.4%	$25.6M+18549.6%	$137K+100.8%	-$17.5M-186.4%	$20.3M-12.3%	$23.1M
Investing Cash Flow	$4.2M+579.4%	-$880K-116.8%	$5.3M+117.3%	-$30.4M-413.5%	$9.7M+374.1%	-$3.5M-327.5%	-$828K+99.8%	-$350.3M
Financing Cash Flow	$656K-84.7%	$4.3M+129.6%	$1.9M-49.2%	$3.7M+43.9%	$2.6M+105.0%	-$51.5M-26115.7%	$198K+124.2%	-$818K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

IMCR Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21
Gross Margin	98.7%-0.4pp	99.1%-0.5pp	99.6%+0.2pp	99.4%-0.6pp	100.0%
Operating Margin	-11.3%+11.4pp	-22.7%+1.2pp	-23.9%+5.7pp	-29.7%+448.9pp	-478.5%
Net Margin	-8.9%+7.6pp	-16.5%+5.7pp	-22.2%+8.0pp	-30.1%+463.3pp	-493.4%
Return on Equity	-9.3%+4.8pp	-14.2%+0.8pp	-15.0%+0.5pp	-15.5%+61.5pp	-77.0%
Return on Assets	-3.3%+1.7pp	-5.1%+4.2pp	-9.3%+0.7pp	-10.0%	N/A
Current Ratio	4.04-0.3	4.38+0.6	3.80-0.9	4.70	N/A
Debt-to-Equity	1.800.0	1.80+1.2	0.62+0.1	0.55	N/A
FCF Margin	-3.8%-10.5pp	6.7%+7.7pp	-1.0%+28.5pp	-29.5%+366.5pp	-396.0%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	99.6%+2.2pp	97.4%-2.1pp	99.5%+0.6pp	98.9%-0.2pp	99.1%-0.5pp	99.6%+0.2pp	99.4%+1.7pp	97.7%
Operating Margin	6.8%+25.7pp	-18.9%-11.9pp	-6.9%+8.3pp	-15.2%-11.3pp	-3.9%+19.3pp	-23.1%-12.6pp	-10.6%+10.7pp	-21.2%
Net Margin	12.2%+40.9pp	-28.8%-28.6pp	-0.2%+10.3pp	-10.5%-15.9pp	5.3%+33.6pp	-28.3%-39.2pp	10.9%+26.3pp	-15.4%
Return on Equity	3.3%+11.2pp	-7.9%-7.8pp	-0.0%+2.6pp	-2.6%-4.0pp	1.3%+7.9pp	-6.6%-8.9pp	2.3%+5.5pp	-3.2%
Return on Assets	1.2%+4.0pp	-2.8%-2.8pp	-0.0%+0.9pp	-0.9%-1.4pp	0.5%+2.8pp	-2.4%-3.2pp	0.8%+1.9pp	-1.1%
Current Ratio	4.18+0.1	4.04-2.0	6.00+0.1	5.89-0.5	6.36+2.0	4.38+0.6	3.78-1.4	5.17
Debt-to-Equity	1.72-0.1	1.80+0.0	1.780.0	1.79+0.1	1.72-0.1	1.80+0.6	1.16-0.1	1.26
FCF Margin	-14.6%+19.4pp	-34.0%-29.0pp	-5.0%-31.1pp	26.1%+25.9pp	0.1%+21.0pp	-20.9%-46.2pp	25.3%-5.4pp	30.7%

Similar Companies

Sarepta Therapeutics Inc SRPT

$2.2B

Mesoblast MESO

$1.9B

Harmony Biosciences Holdings, Inc. HRMY

$2.2B

Dyne Therapeutics, Inc. DYN

$4.0B

Aurinia Pharmace AUPH

$2.1B

Frequently Asked Questions

What is Immunocore Holdings Plc's annual revenue?

Immunocore Holdings Plc (IMCR) reported $400.0M in total revenue for fiscal year 2025. This represents a 29.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Immunocore Holdings Plc's revenue growing?

Immunocore Holdings Plc (IMCR) revenue grew by 29% year-over-year, from $310.2M to $400.0M in fiscal year 2025.

Is Immunocore Holdings Plc profitable?

No, Immunocore Holdings Plc (IMCR) reported a net income of -$35.5M in fiscal year 2025, with a net profit margin of -8.9%.

What is Immunocore Holdings Plc's EBITDA?

Immunocore Holdings Plc (IMCR) had EBITDA of -$42.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Immunocore Holdings Plc's gross margin?

Immunocore Holdings Plc (IMCR) had a gross margin of 98.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Immunocore Holdings Plc's operating margin?

Immunocore Holdings Plc (IMCR) had an operating margin of -11.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Immunocore Holdings Plc's net profit margin?

Immunocore Holdings Plc (IMCR) had a net profit margin of -8.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Immunocore Holdings Plc's return on equity (ROE)?

Immunocore Holdings Plc (IMCR) has a return on equity of -9.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Immunocore Holdings Plc's free cash flow?

Immunocore Holdings Plc (IMCR) generated -$15.1M in free cash flow during fiscal year 2025. This represents a -172.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Immunocore Holdings Plc's operating cash flow?

Immunocore Holdings Plc (IMCR) generated -$10.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Immunocore Holdings Plc's total assets?

Immunocore Holdings Plc (IMCR) had $1.1B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Immunocore Holdings Plc's capital expenditures?

Immunocore Holdings Plc (IMCR) invested $4.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Immunocore Holdings Plc spend on research and development?

Immunocore Holdings Plc (IMCR) invested $274.9M in research and development during fiscal year 2025.

How many shares does Immunocore Holdings Plc have outstanding?

Immunocore Holdings Plc (IMCR) had 51M shares outstanding as of fiscal year 2025.

What is Immunocore Holdings Plc's current ratio?

Immunocore Holdings Plc (IMCR) had a current ratio of 4.04 as of fiscal year 2025, which is generally considered healthy.

What is Immunocore Holdings Plc's debt-to-equity ratio?

Immunocore Holdings Plc (IMCR) had a debt-to-equity ratio of 1.80 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Immunocore Holdings Plc's return on assets (ROA)?

Immunocore Holdings Plc (IMCR) had a return on assets of -3.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Immunocore Holdings Plc's cash runway?

Based on fiscal year 2025 data, Immunocore Holdings Plc (IMCR) had $467.7M in cash against an annual operating cash burn of $10.7M. This gives an estimated cash runway of approximately 524 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Immunocore Holdings Plc's Altman Z-Score?

Immunocore Holdings Plc (IMCR) has an Altman Z-Score of 1.46, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Immunocore Holdings Plc's Piotroski F-Score?

Immunocore Holdings Plc (IMCR) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Immunocore Holdings Plc's earnings high quality?

Immunocore Holdings Plc (IMCR) has an earnings quality ratio of 0.30x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Immunocore Holdings Plc cover its interest payments?

Immunocore Holdings Plc (IMCR) has an interest coverage ratio of -3.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Immunocore Holdings Plc?

Immunocore Holdings Plc (IMCR) scores 66 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.